Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report

The use of immune checkpoint inhibitors has dramatically improved the chance of surviving malignant melanomas; however, the effect comes at the cost of toxicities that are difficult to predict. Immune-mediated hepatitis is the most common form of liver toxicity, but fatal outcome is uncommon. We rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Thorsteinsdottir, Thuridur, Løitegård, Teje, Reims, Henrik Mikael, Porojnicu, Alina Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383158/
https://www.ncbi.nlm.nih.gov/pubmed/32774252
http://dx.doi.org/10.1159/000507695
_version_ 1783563390298357760
author Thorsteinsdottir, Thuridur
Løitegård, Teje
Reims, Henrik Mikael
Porojnicu, Alina Carmen
author_facet Thorsteinsdottir, Thuridur
Løitegård, Teje
Reims, Henrik Mikael
Porojnicu, Alina Carmen
author_sort Thorsteinsdottir, Thuridur
collection PubMed
description The use of immune checkpoint inhibitors has dramatically improved the chance of surviving malignant melanomas; however, the effect comes at the cost of toxicities that are difficult to predict. Immune-mediated hepatitis is the most common form of liver toxicity, but fatal outcome is uncommon. We report the case of a 70-year-old female with metastatic malignant melanoma who developed severe liver toxicity characterized by bile duct injury and cholestasis. The condition progressed despite potent immunosuppressive treatment, plasmapheresis, and intensive supportive care; and the patient died while still having tumor response.
format Online
Article
Text
id pubmed-7383158
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-73831582020-08-07 Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report Thorsteinsdottir, Thuridur Løitegård, Teje Reims, Henrik Mikael Porojnicu, Alina Carmen Case Rep Oncol Case Report The use of immune checkpoint inhibitors has dramatically improved the chance of surviving malignant melanomas; however, the effect comes at the cost of toxicities that are difficult to predict. Immune-mediated hepatitis is the most common form of liver toxicity, but fatal outcome is uncommon. We report the case of a 70-year-old female with metastatic malignant melanoma who developed severe liver toxicity characterized by bile duct injury and cholestasis. The condition progressed despite potent immunosuppressive treatment, plasmapheresis, and intensive supportive care; and the patient died while still having tumor response. S. Karger AG 2020-06-15 /pmc/articles/PMC7383158/ /pubmed/32774252 http://dx.doi.org/10.1159/000507695 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Thorsteinsdottir, Thuridur
Løitegård, Teje
Reims, Henrik Mikael
Porojnicu, Alina Carmen
Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report
title Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report
title_full Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report
title_fullStr Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report
title_full_unstemmed Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report
title_short Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report
title_sort fatal cholestatic liver injury during treatment with pd1 immune checkpoint inhibitor for malignant melanoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383158/
https://www.ncbi.nlm.nih.gov/pubmed/32774252
http://dx.doi.org/10.1159/000507695
work_keys_str_mv AT thorsteinsdottirthuridur fatalcholestaticliverinjuryduringtreatmentwithpd1immunecheckpointinhibitorformalignantmelanomaacasereport
AT løitegardteje fatalcholestaticliverinjuryduringtreatmentwithpd1immunecheckpointinhibitorformalignantmelanomaacasereport
AT reimshenrikmikael fatalcholestaticliverinjuryduringtreatmentwithpd1immunecheckpointinhibitorformalignantmelanomaacasereport
AT porojnicualinacarmen fatalcholestaticliverinjuryduringtreatmentwithpd1immunecheckpointinhibitorformalignantmelanomaacasereport

Ejemplares similares